Cargando…

Correction: Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501959/ https://www.ncbi.nlm.nih.gov/pubmed/31048451 http://dx.doi.org/10.1136/bmjopen-2015-009183corr1

Ejemplares similares

Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2015)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

Prescribing Patterns for Long-Acting Inhaled Bronchodilators Among Rural Adults With Chronic Obstructive Pulmonary Disease
por: Brunner, Wendy M., et al.
Publicado: (2022)

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids
por: Asche, Carl Victor, et al.
Publicado: (2012)

Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population
por: Tsai, Ming-Jun, et al.
Publicado: (2015)

Risk of adverse cardiovascular events with use of inhaled long-acting bronchodilators in management of chronic obstructive pulmonary disease
por: Wang, Meng-Ting, et al.
Publicado: (2019)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectiveness Research
por: Mapel, Douglas W., et al.
Publicado: (2014)

Correction: Certified Registered Nurse Anesthetists’ occupational exposure to inhalational anesthetic agents: a survey of anesthetic gas safety
por: Masselink, Trent, et al.
Publicado: (2023)

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
por: Tashkin, Donald P, et al.
Publicado: (2010)

Long-acting Inhaled Bronchodilator and Risk of Vascular Events in Patients With Chronic Obstructive Pulmonary Disease in Taiwan Population: Erratum
Publicado: (2016)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Correction: Clinical characteristics and predictors of pulmonary hypertension in chronic obstructive pulmonary disease at different altitudes
por: Wang, Lixia, et al.
Publicado: (2023)

Correction: Circulating Progenitor Cells and Vascular Dysfunction in Chronic Obstructive Pulmonary Disease
Publicado: (2014)

Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
por: Rossi, Andrea, et al.
Publicado: (2008)

The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease
por: Decramer, Marc L, et al.
Publicado: (2013)

Correction: Effect of PIFR-based optimised inhalation therapy in patients recovering from acute exacerbation of chronic obstructive pulmonary disease: protocol of a prospective, multicentre, superiority, randomised controlled trial
Publicado: (2020)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Correction: Evaluation of asthma–chronic obstructive pulmonary disease overlap using a mouse model of pulmonary disease
por: Jo, Yong Suk, et al.
Publicado: (2023)

Correction to: Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis
por: El Baou, Céline, et al.
Publicado: (2017)

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2014)

Adherence to Long-Acting Inhaler Use for Initial Treatment and Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study
por: Suh, Hee-Sook, et al.
Publicado: (2022)

Chronic obstructive pulmonary disease caused by inhalation of dust: A meta-analysis
por: Peng, Cong, et al.
Publicado: (2020)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
por: Donohue, James F, et al.
Publicado: (2017)

Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2023)

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS)
Publicado: (2013)

Correction: Suppressed Expression of T-Box Transcription Factors Is Involved in Senescence in Chronic Obstructive Pulmonary Disease
Publicado: (2017)

Correction: How Reliable Are Current Data for Assessing the Actual Prevalence of Chronic Obstructive Pulmonary Disease?
por: Romanelli, Anna Maria, et al.
Publicado: (2016)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
por: Burkes, Robert M, et al.
Publicado: (2020)

Risk of Pneumonia with Inhaled Corticosteroid versus Long-Acting Bronchodilator Regimens in Chronic Obstructive Pulmonary Disease: A New-User Cohort Study
por: DiSantostefano, Rachael L., et al.
Publicado: (2014)

Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β(2)-agonists in patients with asthma and chronic obstructive pulmonary disease
por: Olszanecka-Glinianowicz, Magdalena, et al.
Publicado: (2020)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease
por: Janson, Christer
Publicado: (2020)

The future of inhalation therapy in chronic obstructive pulmonary disease
por: Cazzola, Mario, et al.
Publicado: (2022)

Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β(2)-agonists in the United Kingdom: a cross-sectional analysis
por: Pavord, Ian D., et al.
Publicado: (2017)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

Chronic obstructive pulmonary disease patients’ experience using Trelegy as compared with other inhalers
por: Mashaal, Hyfaa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2o0sb4emjsqlhaqup0tarnieus